Income Statement (LYELL/IMMUNOPHARMA)

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report issued on Saturday. Separately, H… [+3079 chars]...

SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cance… [+8072 chars]...

• Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma
• In… [+30289 chars]...
  Read more

New York, USA, Aug. 18, 2025 (GLOBE NEWSWIRE) -- PD-(L)1 Inhibitors Market Set to Surge During the Forecast Period (20252034) as Immuno-Oncology Therapies Gain Momentum | DelveInsight  PD-1 inhibito… [+22405 chars]...